On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab and hylaluronidase-lpuj (Rybrevant Faspro, Johnson & Johnson) for adults head and neck squamous cell carcinoma (HNSCC) that has spread to other parts of the body (metastatic) or has come back (recurrent) and has progressed on or after platinum-based chemotherapy and immunotherapy. This is the first approval in 10 years for these patients and the only dual-targeted therapy for advanced HNSCC.
Head and neck squamous cell carcinoma is a cancer that develops in the head and neck. It can affect the oral cavity, pharynx, hypopharynx, larynx, nasal cavity, and salivary glands. Globally, around 890,000 people were diagnosed with HNSCC. For people whose HNSCC comes back after treatment (recurrent) or spreads to other parts of the body (metastatic), treatment options are limited.
Around 80% to 90% of people with metastatic or recurrent HNSCC have EGFR and MET mutations. This targeted therapy is directed at both of these changes.
“Outcomes remain poor for patients whose head and neck cancer progresses, and treatment options are limited. The OrigAMI-4 findings represent important progress and highlight the potential of dual EGFR- and MET-targeting with amivantamab as a distinct treatment approach in recurrent or metastatic head and neck cancer, excluding HPV-associated oropharyngeal squamous cell carcinoma. The meaningful responses observed in this study are encouraging for patients who have long faced limited treatment options.”
Said Dr. Barabara Burtness of Yale Cancer Center in a press release about the approval.
How does amivantamab and hylaluronidase-lpuj (Rybrevant Faspro) treat HNSCC?
Amivantamab is a type of targeted therapy called a bispecific monoclonal antibody. It targets epidermal growth factor receptor (EGFR) and MET genetic changes. It binds to the surface of cancer cells and stops cancer cells from growing. Hylaluronidase-lpuj is an enzyme that helps the body absorb amivantamab.
OrigAMI-4: The study that led to the amivantamab and hylaluronidase-lpuj approval
This approval was based on the phase 1b/2 OrigAMI-4 clinical trial. It included 102 adults with previously treated recurrent or metastatic HNSCC. The patients had received platinum-based chemotherapy and an anti-PD-(L)1 antibody. The trial did not include any patients with HPV-related oropharyngeal squamous cell carcinoma.
The overall response rate was 42%. Of those, 15% had a complete response, meaning there were no signs of cancer after treatment. For more than half of those who had a response (56%), treatment continued to control the cancer for more than six months.
What are the common side effects of amivantamab and hylaluronidase-lpuj?
The most common side effects of amivantamab and hylaluronidase-lpuj were:
Rash
Fatigue
Nail problems
Mouth sores and inflammation
Swelling
Some patients experienced severe side effects. These included:
Pneumonia
Bleeding
Difficulty swallowing
Collapsed lung
Anemia
Fever
Fatigue
Increased liver enzymes
Lung inflammation (interstitial lung disease)
Fatal side effects happened in 6% of patients.
Questions to ask your care team about amivantamab and hylaluronidase-lpuj
If you or a loved one has HNSCC, ask your healthcare team about amivantamab and hylaluronidase-lpuj (Rybrevant Faspro) or ongoing clinical trials. Consider asking your care team the following questions:
Am I eligible for treatment with amivantamab and hyaluronidase-lpuj based on my cancer type and treatment history?
How does this treatment compare to other options available to me?
What side effects should I be aware of?
SOURCES:
US FDA: FDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell Carcinoma
Med Sci: Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma


